Drug intelligence / Profile preview

azithromycin + probiotics

Development stage: Unknown
Lead developer: Hayatabad Medical Complex
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This combination therapy consists of the macrolide antibiotic azithromycin and oral probiotics, being investigated for the treatment of mild to moderate acne vulgaris. Azithromycin exerts its effect by binding to the 50S ribosomal subunit of susceptible bacteria, such as *Cutibacterium acnes*, thereby inhibiting protein synthesis and reducing inflammation. The addition of probiotics is intended to modulate the gut-skin axis, potentially reducing systemic inflammation and counteracting the dysbiosis often associated with long-term antibiotic use. This specific regimen is being evaluated in a Phase 4 clinical trial sponsored by the Hayatabad Medical Complex to compare its efficacy against azithromycin monotherapy in managing lesion counts and improving patient outcomes.

Other names: azithromycin and probiotics combination

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on azithromycin + probiotics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azithromycin + probiotics.

Explore the full profile